STA
AZN icon

Summit Trail Advisors’s AstraZeneca AZN Stock Holding History

Summit Trail Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71M Sell
19,747
-372
-2% -$70K 0.05% 273
2026
Q1 		$3.91M Buy
20,119
+15,262
+314% +$2.94M 0.06% 221
2025
Q4 		$893K Sell
4,857
-1,304
-21% -$229K 0.02% 872
2025
Q3 		$945K Buy
6,161
+485
+9% +$73.4K 0.01% 863
2025
Q2 		$793K Buy
+5,676
New +$795K 0.01% 558
2024
Q4 		– Sell
-3,838
Closed -$598K – 432
2024
Q3 		$598K Sell
3,838
-461
-11% -$74.4K 0.01% 358
2024
Q2 		$670K Buy
4,299
+1,080
+34% +$163K 0.02% 312
2024
Q1 		$436K Sell
3,219
-300
-9% -$39.7K 0.01% 365
2023
Q4 		$474K Buy
3,519
+136
+4% +$17.7K 0.02% 294
2023
Q3 		$458K Sell
3,383
-1,633
-33% -$223K 0.02% 291
2023
Q2 		$718K Buy
5,016
+2,465
+97% +$363K 0.03% 206
2023
Q1 		$354K Buy
+2,551
New +$343K 0.01% 288
2022
Q2 		– Sell
-1,803
Closed -$239K – 389
2022
Q1 		$239K Sell
1,803
-456
-20% -$54.7K 0.02% 279
2021
Q4 		$263K Buy
2,259
+460
+26% +$54.1K 0.02% 246
2021
Q3 		$216K Buy
+1,799
New +$209K 0.02% 243
2018
Q4 		– Sell
-2,349
Closed -$186K – 127
2018
Q3 		$186K Buy
+2,349
New +$178K 0.04% 191
2018
Q2 		– Sell
-8,846
Closed -$302K – 501
2018
Q1 		$302K Buy
8,846
+686
+8% +$47.5K 0.05% 279
2017
Q4 		$578K Buy
+8,160
New +$550K 0.07% 208

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Summit Trail Advisors's AZN Position: Q2 2026 in Review

Summit Trail Advisors reduced its AstraZeneca (AZN) stake by 1.8% in Q2 2026, selling an estimated $70K and leaving 19,747 shares worth $3.71M. The position accounts for 0.05% of the portfolio, ranked #273.

Summit Trail Advisors first reported a position in AZN in Q4 2017 and has held it in 18 quarters since. The position peaked at $3.91M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Summit Trail Advisors held 19,747 shares of AstraZeneca worth $3.71M as of Q2 2026.
  • Summit Trail Advisors sold 372 AstraZeneca shares in Q2 2026, an estimated $70K.
  • AstraZeneca made up 0.05% of Summit Trail Advisors's portfolio in Q2 2026, its #273 holding.
  • Summit Trail Advisors first reported a position in AstraZeneca in Q4 2017 and has held it in 18 quarters since.
  • Summit Trail Advisors's AstraZeneca position peaked at $3.91M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.